ArticleHepatology communications2026
Natural Killer T cells promote cholestatic liver disease independent of antigen presentation by cholangiocytes.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNatural killer T (NKT) cells are an important lymphocyte subset in the liver that can be activated by CD1d-restricted lipid antigens presented on cholangiocytes, including lipids in bile from patients with chronic liver diseases. We hypothesized that during cholestasis, NKT cells play an essential role in the pathophysiology.
methodsWe explored this immune pathway by ligating the common bile duct (BDL) in CD1d knockout (Cd1d-/-) mice, Traj18-/- mice, wild-type (WT) mice, and created a novel model with conditional deletion of CD1d on cholangiocytes (Cd1dΔCC mice).
resultsFollowing BDL, we observed a clear and specific activation of hepatic NKT cells. Cd1d-/- mice, depleted of both invariant and noninvariant NKT cells, were protected from BDL-induced cholestatic liver damage. In contrast, Traj18-/- mice, lacking only invariant natural killer T cells, were not protected as compared with WT mice. Cd1dΔCC mice exhibited a deficiency in functional CD1d expression on cholangiocytes but had a comparable distribution and phenotype of NKT cells as WT mice. After BDL, Cd1dΔCC mice were not protected and developed similar liver disease as WT mice.
conclusionsA subset of hepatic NKT cells contributes to cholestatic liver disease, and their activation is independent of CD1d antigen presentation on cholangiocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.